{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:29:20Z","timestamp":1782289760832,"version":"3.54.5"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T00:00:00Z","timestamp":1366243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,6]]},"abstract":"Summary<\/jats:title>Dexamethasone\u00a0\u00b1\u00a0thalidomide with infusion of cisplatin, doxorubicin, cyclophosphamide, and etoposide [D(T)PACE<\/jats:styled-content>] is generally reserved as salvage therapy for aggressive multiple myeloma (MM<\/jats:styled-content>) or plasma cell leukaemia (PCL<\/jats:styled-content>) resistant to conventional therapies. The efficacy and durability of this potentially toxic regimen in this setting is unclear. We identified 75 patients who received D(T)PACE<\/jats:styled-content> for relapsed\/refractory MM<\/jats:styled-content> at two tertiary care centres: P<\/jats:styled-content>rincess M<\/jats:styled-content>argaret H<\/jats:styled-content>ospital, T<\/jats:styled-content>oronto and M<\/jats:styled-content>ayo C<\/jats:styled-content>linic A<\/jats:styled-content>rizona. At time of D(T)PACE<\/jats:styled-content>, 16 patients had PCL<\/jats:styled-content> and three patients had leptomeningeal disease. Patients were heavily pretreated (median three prior regimens, range 1\u201312; prior autologous stem cell transplant [ASCT<\/jats:styled-content>] 33%). Overall response rate was 49% (very\u2010good partial response 16%, partial response 33%) with stable disease in an additional 36%. Median progression\u2010free survival (PFS<\/jats:styled-content>) was 5\u00b75\u00a0months (95% confidence interval [CI<\/jats:styled-content>]:4\u00b73\u20139\u00b78); overall survival (OS<\/jats:styled-content>) 14\u00b70\u00a0months (95% CI<\/jats:styled-content>:8\u00b77\u201319\u00b73). Thirty\u2010five patients proceeded to ASCT<\/jats:styled-content> or clinical trial, with median PFS<\/jats:styled-content> for this subset of 13\u00b74\u00a0months (95% CI<\/jats:styled-content>:7\u00b77\u201320\u00b71) and OS<\/jats:styled-content> 20\u00b75\u00a0months (95% CI<\/jats:styled-content>:14\u00b78\u201363\u00b78). D(T)PACE<\/jats:styled-content> is an effective salvage therapy for heavily pretreated MM<\/jats:styled-content> patients. Although the overall response rate of 49% in this poor prognosis cohort is reasonable, the PFS<\/jats:styled-content> is short, suggesting the best role for D(T)PACE<\/jats:styled-content> is in bridging to definitive therapy, such as transplantation.<\/jats:p>","DOI":"10.1111\/bjh.12325","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T10:52:13Z","timestamp":1366282333000},"page":"802-810","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["D(T)PACE<\/scp> as salvage therapy for aggressive or refractory multiple myeloma"],"prefix":"10.1111","volume":"161","author":[{"given":"Alina S.","family":"Gerrie","sequence":"first","affiliation":[{"name":"Hematology University of British Columbia Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Mikhael","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Mayo Clinic Arizona Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Biostatistics Princess Margaret Hospital Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Division of Biostatistics Princess Margaret Hospital Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Kukreti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Hospital Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Panzarella","sequence":"additional","affiliation":[{"name":"Division of Biostatistics Princess Margaret Hospital Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Hospital Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Mayo Clinic Arizona Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Trieu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Hospital Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Hospital Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine I.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Hospital Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4,18]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Survival Analysis Using SAS: Practical Guide","author":"Allison P.D.","year":"2010"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053583"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06639.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/01621459.1977.10479903","article-title":"Covariance analysis of heart transplant survival data","volume":"27","author":"Crowley J.","year":"1977","journal-title":"Journal of the American Statistical Association"},{"key":"e_1_2_8_6_1","first-page":"41","article-title":"Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients","volume":"12","author":"Dadacaridou M.","year":"2007","journal-title":"Journal of BUON"},{"key":"e_1_2_8_7_1","first-page":"LBA","article-title":"Pomalidomide in combination with low\u2010dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed\/refractory MM: a phase 3, multicenter, randomized, open\u2010lable study","volume":"120","author":"Dimopoulos M.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.307"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404428"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.20.1.145"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.9158"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.055"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06921.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/asheducation.V2012.1.354.3798330","article-title":"Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?","volume":"2012","author":"Rajkumar S.V.","year":"2012","journal-title":"American Society of Hematology Education Program"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1853"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01131.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.06982.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12325","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:35:11Z","timestamp":1698640511000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,18]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/bjh.12325"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12325","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,18]]},"assertion":[{"value":"2012-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-04-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}